Ligand Pharmaceuticals Incorporated
LGND
$193.03
-$2.07-1.06%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 7.38% | -280.02% | -237.65% | -107.73% | 174.52% |
| Total Depreciation and Amortization | -3.77% | -5.38% | -3.82% | -3.51% | -8.29% |
| Total Amortization of Deferred Charges | 18.70% | 29.46% | 38.20% | 32.25% | -0.69% |
| Total Other Non-Cash Items | -2,728.03% | 2,214.45% | 314.88% | 757.65% | -94.33% |
| Change in Net Operating Assets | -25.68% | 120.40% | 117.46% | 156.26% | -200.93% |
| Cash from Operations | -58.36% | 15.91% | 53.87% | 95.75% | -19.31% |
| Capital Expenditure | 24.31% | -22.51% | -59.24% | 48.28% | 70.85% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | 100.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -248.58% | -16.56% | -824.77% | -6,420.99% | -1,735.51% |
| Cash from Investing | -244.97% | -2.92% | -419.09% | -1,129.79% | -1,228.32% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -471,883.33% | -7.14% | 99.96% | 99.97% | 99.97% |
| Issuance of Common Stock | 9.07% | 257.68% | 265.77% | 509.22% | 401.11% |
| Repurchase of Common Stock | -657.37% | -222.93% | -215.77% | -12.95% | 46.87% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 2,094.19% | -2,528.56% | -3,383.43% | -3,530.77% | 71.61% |
| Cash from Financing | 436.48% | 183.28% | 270.70% | 262.04% | 216.31% |
| Foreign Exchange rate Adjustments | 271.88% | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 73.12% | 580.59% | 94.55% | 323.80% | 177.99% |